AMENDMENTS TO THE CLAIMS

1. (Currently amended) A purified compound having the following formula



wherein the compound is isolated from an ascidian;

n is 2 to 6; Q is NH or O;

R_1 is H or piperazine;

~~positions 1, 4, 5, and 8 are optionally substituted with halogen, amine, amino, imino, carboxylic acid or amide,~~

and tautomers, stereoisomers, anhydrides, and pharmaceutically acceptable salts thereof.

2. (Previously Presented) A purified compound having the following formula:



wherein n is 2 to 6; Q is NH or O; and R_1 is H or piperazine, and pharmaceutically acceptable salts thereof.

3. (Withdrawn) A process for the preparation of a compound according to claim 1 which comprises subjecting an ascidian to solvent extraction.

4. (Withdrawn) A process as claimed in claim 3 wherein said ascidian is *Synoicum macroglossum*.

5. (Withdrawn) A process as claimed in claim 3 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

6. (Withdrawn) A process as claimed in claim 5 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

7. (Withdrawn) A process as claimed in claim 6 wherein said dichloromethane and methanol are used in a ratio of 1:1.

8. (Withdrawn) A process as claimed in claim 7 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

9. (Withdrawn) A process as claimed in claim 8 wherein said water extract is lyophilized and the residue is triturated with methanol.

10. (Withdrawn) A process as claimed in claim 5 wherein said purification comprises a Sephadex LH-20 column chromatography.

11. (Previously presented) A pharmaceutical composition comprising as an active ingredient a compound according to claim 1, and a pharmaceutically acceptable carrier, vehicle or excipient.

12. (Previously presented) A pharmaceutical composition comprising as an active ingredient a compound according to claim 2 and a pharmaceutically acceptable carrier, vehicle or excipient.

13. (Previously presented) A composition as claimed in claim 11 wherein said active ingredient is present in an amount of about 78.8 μg.

14. (Previously presented) A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

15. (Withdrawn) A pharmaceutical composition comprising a first therapeutic agent consisting of a compound according to claim 2 and a second therapeutic agent different from said first therapeutic agent.

16. (Withdrawn) A composition as claimed in claim 15 wherein said second therapeutic agent is selected from alkylating agents, antimetabolites, vinca alkaloids, antibiotics, cytokines, growth factors and non-steroidal anti-inflammatory drugs.

17. (Withdrawn) A method of treating diabetic disorders in a mammal in need thereof wherein the method comprises administration of a compound according to claim 2.

18. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a compound according to claim 2.

19. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 11.

20. (Previously presented) A composition as claimed in claim 13 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

21. (Previously presented) A composition as claimed in claim 12 wherein said active ingredient is present in an amount of about 78.8 μg.

22. (Previously presented) A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 24 mg to about 280 mg.

23. (Previously presented) A composition as claimed in claim 21 wherein the unit dosage of said composition is from about 15 mg to about 480 mg.

24. (Withdrawn) A process as claimed in claim 4 wherein said extraction comprises extraction in the presence of methanol followed by a dichloromethane:methanol extraction and the extract so obtained is subject to purification.

25. (Withdrawn) A process as claimed in claim 24 wherein said ascidian comprises freeze dried *Synoicum macroglossum*.

26. (Withdrawn) A process as claimed in claim 25 wherein said dichloromethane and methanol are used in a ratio of 1:1.

27. (Withdrawn) A process as claimed in claim 26 wherein after extraction with dichloromethane and methanol, the extract so obtained is partitioned between water and ethyl acetate.

28. (Withdrawn) A process as claimed in claim 27 wherein said water extract is lyophilized and the residue is triturated with methanol.

29. (Withdrawn) A process as claimed in claim 6 wherein said purification comprises a Sephadex LH-20 column chromatography.

30. (Withdrawn) A process as claimed in claim 7 wherein said purification comprises a Sephadex LH-20 column chromatography.

31. (Withdrawn) A process as claimed in claim 8 wherein said purification comprises a Sephadex LH-20 column chromatography.

32. (Withdrawn) A process as claimed in claim 9 wherein said purification comprises a Sephadex LH-20 column chromatography.

33. (Withdrawn) A process as claimed in claim 24 wherein said purification comprises a Sephadex LH-20 column chromatography.

34. (Withdrawn) A process as claimed in claim 25 wherein said purification comprises a Sephadex LH-20 column chromatography.

35. (Withdrawn) A process as claimed in claim 26 wherein said purification comprises a Sephadex LH-20 column chromatography.

36. (Withdrawn) A process as claimed in claim 27 wherein said purification comprises a Sephadex LH-20 column chromatography.

37. (Withdrawn) A process as claimed in claim 28 wherein said purification comprises a Sephadex LH-20 column chromatography.

38. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 12.

39. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 13.

40. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 14.

41. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 15.

42. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 16.

43. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 20.

44. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 21.

45. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 22.

46. (Withdrawn) A method of treating a mammal which comprises administering to a mammal in need thereof an effective amount of a pharmaceutical composition as claimed in claim 23.

47. (Withdrawn) A composition as claimed in claim 16, wherein the non-steroidal anti-inflammatory is aspirin.

48. (Currently amended) A ~~purified~~ compound having the following formula



~~wherein the compound is isolated from an ascidian;~~

wherein n is 2 to 6; Q is NH or O;

R_1 is H or piperazine;

and at least one of positions 1, 4, 5, and 8 is substituted with halogen, amine, amino, imino, carboxylic acid or amide,

and tautomers, stereoisomers, anhydrides, and pharmaceutically acceptable salts thereof.

49. (Previously presented) A pharmaceutical composition comprising a compound according to claim 48 as an active ingredient, and a pharmaceutically acceptable carrier, vehicle or excipient.

50. (Previously presented) The composition of claim 49, wherein the active ingredient is present in an amount of about 78.8 μg.

51. (Previously presented) The composition of claim 50, wherein the unit dosage of the composition is from about 15 mg to about 480 mg.

52. (Previously presented) The composition of claim 50, wherein the unit dosage of the composition is from about 24 mg to about 280 mg.